Black Diamond Therapeutics, Inc. (BDTX) - Dilution Analysis

10-Q filing | 57.2M shares outstanding

10-K filing | 57.6M shares outstanding

S-3 filing: The filing is an S-3 form for a shelf offering allowing the company to offer and sell up to $500,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units.

10-Q filing | 56.9M shares outstanding

10-Q filing | 56.8M shares outstanding

10-Q filing | 56.7M shares outstanding

10-K filing | 55.0M shares outstanding

10-Q filing | 56.5M shares outstanding

10-Q filing | 55.2M shares outstanding

10-Q filing | 51.8M shares outstanding

10-K filing | 51.7M shares outstanding

10-Q filing | 50.9M shares outstanding

10-Q filing | 51.6M shares outstanding

8-K filing: Black Diamond Therapeutics, Inc. entered into an underwriting agreement to issue and sell up to 15,000,000 shares of common stock in an underwritten public offering at a public offering price of $5.00 per share. ($86.25M proceeds)

10-Q filing | 36.5M shares outstanding

10-K filing | 36.3M shares outstanding

8-K filing: Black Diamond Therapeutics, Inc. formed Launchpad Therapeutics, Inc. and received 9.0 million shares of Launchpad common stock in exchange for contributing antibody programs and granting a license to its MAP Drug Discovery Engine.

S-3 filing: The company may offer and sell up to $500,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units. The company may also offer common stock with an aggregate offering price of up to $150,000,000 through Jefferies LLC.

10-Q filing | 36.3M shares outstanding

10-Q filing | 36.3M shares outstanding

10-Q filing | 36.3M shares outstanding

10-K filing | 36.2M shares outstanding

10-Q filing | 36.2M shares outstanding

10-Q filing | 36.2M shares outstanding

10-Q filing | 36.1M shares outstanding

10-K filing | 36.1M shares outstanding

10-Q filing | 36.0M shares outstanding

10-Q filing | 35.9M shares outstanding

10-Q filing | 35.9M shares outstanding

10-K filing | 35.9M shares outstanding

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock, with an underwriters' option to purchase additional shares. The company intends to use the net proceeds to fund the Phase 1/2 development of BDTX-189, to identify a lead development candidate and conduct IND-enabling studies in our glioblastoma program and for continued development of our discovery programs and our MAP platform, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.

S-1 filing: This S-1 filing indicates an offering of common stock with J.P. Morgan, Jefferies, Cowen, and Canaccord Genuity as underwriters, and the company intends to use the proceeds to fund development programs and for general corporate purposes.